US/UK/Canada

Share

Quotes

“The surgery was done by the book by Mr Paul Culpan. We’re delighted to be collaborating with him, The London Clinic and London International Patient Services. It’s an exciting restart for the OPRA™ Implant System program in the U.K. and we hope that this surgery will pave the way for a deeper collaboration moving forward.
Professor Rickard Brånemark
...the treatment of thumb amputees using bone-anchored percutaneous prostheses with the osseointegration technique seems to be a safe, durable method with excellent short- and medium-long follow-up results.
JAAOS study
Osseointegration is a potentially game changing technology in amputee care, and Dr Brånemark is bringing the most advanced osseointegration technology to our group
Professor Hugh Herr, Head of the MIT Media Lab Biomechatronics Group
We are very happy to have Blake join us to strengthen our team and our presence in the hugely important North American market.
Rutger Barrdahl, CEO at Integrum
Pick a time period -
Tags ( Active)

Integrum implements a write-down of approximately SEK 7 million following reclassification of certain inventory items

Mölndal, Sweden, April 30, 2026 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) today announces that, as part of preparing the annual financial statements for the 2025/2026 fiscal year, the company has decided to recognize an impairment charge of approximately SEK 7 million following a reclassification of certain inventory items. The write-down will affect earnings for the fourth quarter of 2025/2026 but will have no impact on the company’s cash flow.Integrum has elected to reclassify certain inventory items related to instruments used in the implantation of the company's

Integrum accelerates Ukraine expansion following landmark decision to expand osseointegration treatment in national healthcare

Mölndal, Sweden, April 15, 2026 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) today announces the appointment of Victoria Boiko to coordinate the company’s commercial activities in Ukraine. The appointment comes as Ukraine’s Ministry of Health prepares a national pilot project to integrate osseointegration into the public healthcare system, a development that could significantly expand access to the technology for amputees across the country.“Ukraine's ambition to make osseointegration part of its national healthcare system is a milestone – not only for the patients who

Integrum publishes Interim Report for the third quarter 2025/26

Mölndal, 5 March 2026 – Integrum (publ) today publishes its interim report for the third quarter 2025/26. During the quarter, the structural transformation was completed and the company now enters the next phase with focus on execution, growth and improved profitability.+----------------------------+--------------------------+|Third quarter 2025/26 |1 May 2025 – 31 January ||(November – January) |2026 || |(9 months) ||Net sales amounted to SEK | ||20,2 (23,7) million

Integrum invites to presentation of Q3 2025/26 results

Mölndal, Sweden – March 3, 2026 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a live webcast presentation of its third quarter 2025/26 results on Thursday, March 5, 2026, at 10:00 CET.CEO Martin Hillsten will present the report together with CFO Louise Wåhlin. Participants will have the opportunity to ask questions during the webcast.The webcast can be accessed at:https://www.finwire.tv/webcast/integrum/q3-2025/ The report will be available at:https://integrum.se/investor-relations/financial-reports-calendar/

Integrum optimizes organization to further accelerate commercialization of OPRA Implant System

Mölndal, Sweden, February 11, 2026 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company is implementing organizational changes to accelerate the commercialization of OPRA® Implant System and streamline its global production and supply chain. The changes are being made within the framework of the strategy presented in 2025. In connection with this, Jeff Zanni, President US, is leaving the company. At the same time, Dr Rickard Brånemark takes on the role as Chief Medical and Scientific Officer on a consulting basis, with responsibility for leading

Integrum’s rights issue oversubscribed

Integrum AB (publ) ("Integrum" or the "Company") announced on October 16, 2025 that the Board of Directors had resolved to carry out an issue of shares of series B with preferential right for existing shareholders of up to approximately SEK 42.7 million (the "Rights Issue"). The Board of Directors’ resolution on the Rights Issue was approved at the extraordinary general meeting of the Company held on November 10, 2025. Integrum hereby announces that subscription by exercise of and through application of subscription without subscription rights amount to 18,711,946 shares, corresponding to

Integrum publishes Interim Report for Q2 2025/26

Second Quarter 2025/26 (August – October) · Net sales amounted to SEK 22.3 (21.8) million. · Operating result totalled SEK -11.1 (-11.3) million. · Profit/loss after tax amounted to SEK -7.4 (-8.9) million. · Earnings per share amounted to SEK -0.35 (-0.46) · Cash flow totalled SEK -19.4 (-12.0) million. 1 May 2025 – 31 October 2025 (6 months) · Net sales amounted to SEK 46.1 (40.2) million. · Operating result totalled SEK -23.6 (-23.3) million. · Profit/loss after tax amounted to SEK -17.4 (-18.4) million. · Earnings per share amounted to SEK -0.82 (-0.95)

Integrum AB: Invitation to the Second Quarter 2025/26 Results Presentation

Mölndal, Sweden – November 19, 2025 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its second quarter 2025/26 results on November 21, 2025 at 10:00 CET.Integrum’s CEO Martin Hillsten will present the report together with CFO Louise Wåhlin in a webcast. The presentation will be held in English. Time: Friday, November 21, 2025 at 10:00 CET. Location: Webcast (see link below). The report will be available at https://integrum.se/investor-relations/financial-reports-calendar/ The webcast and presentation material will be accessible

The subscription period in Integrum’s rights issue has begun

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, REQUIRE REGISTRATION OR ANY OTHER MEASURES. November 17, 2025, was the first day of the subscription period in Integrum AB’s ("Integrum" or the "Company") rights issue of shares of series B that was resolved by the Board of Directors on

Integrum publishes information document regarding rights issue

Integrum AB (publ) ("Integrum" or the "Company") (Nasdaq First North Growth Market) publishes information document relating to the rights issue of shares of approximately SEK 42.6 million before deduction of issue costs, which was resolved by the Board of Directors on October 16, 2025, and approved by the extraordinary general meeting on November 10, 2025 (the “Rights Issue”).Information document In connection with the Rights Issue, the Company has prepared an information document (the “Information Document”) in accordance with Article 1.4 db of Regulation (EU) 2017/1129 of the European

Integrum publishes preliminary financial key figures for the second quarter 2025/26

Mölndal, 13 November 2025 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B), today publishes, in connection with the ongoing rights issue, preliminary and unaudited financial key figures for the second quarter (August–October 2025) ahead of the interim report scheduled for publication on 21 November 2025.Preliminary financial results, Q2 2025/26 (Aug–Oct 2025) · Net sales: SEK 22.3 million (21.8), an increase of 2.6%. · Operating result (EBIT): SEK -11.1 million (-11.3). · Result after tax: SEK -7.4 million (-8.9). · Earnings per share: SEK -0.35 (-0.46). ·

Integrum enters into bridge loan agreement to cover short-term working capital needs

Integrum AB (publ) (“Integrum” or the “Company”) has today entered into an agreement for a bridge loan of up to SEK 7 million with Buntel AB. The purpose of the loan is to cover the Company’s short-term working capital needs during the period until the completion of the rights issue, resolved by the Company’s extraordinary general meeting on November 10, 2025 (the “Rights Issue”).In order to cover the Company's short-term working capital needs until the proceeds from the Rights Issue are received by the Company, the Company has entered into an agreement regarding a bridge loan of up to SEK

Integrum announces organizational restructuring to strengthen its commercial focus

Mölndal, Sweden, October 23, 2025 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) today announced a strategic organizational restructuring to accelerate the commercialization of OPRA™ Implant System and improve operational efficiency. As part of this process, the company has initiated the statutory consultation required under Swedish employment law regarding a proposed reduction of six positions, which accounts for about 20 percent of its current workforce in Sweden. This restructuring supports the strategic shift announced by Integrum in February 2025 and reflects the

Integrum announces that the Swedish Securities Council has published a statement regarding the takeover offer for Integrum

Mölndal, Sweden, October 20, 2025 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) notes that, in statement 2025:45 dated October 17, 2025, the Swedish Securities Council (Aktiemarknadsnämnden) declared that the bidder OsteoCentric violated the takeover rules and thus acted contrary to good practice in the securities market by failing to take sufficient measures to work toward satisfaction of the completion condition requiring at least 90 percent acceptance. The Council directs serious criticism at the bidder.The Council emphasizes that the obligation to work toward the

Integrum resolves on a rights issue of shares of series B of approximately SEK 42.6 million subject to approval by extraordinary general meeting and earlier release of Q2 report

The Board of Directors of Integrum AB (publ) (“Integrum” or the “Company”) has today resolved to carry out a share issue of approximately SEK 42.6 million before deduction of issue costs with preferential rights for existing shareholders (the “Rights Issue”). Integrum is currently undergoing a transformative journey, from a development-driven company to a streamlined and commercially focused organization. The new strategic direction, which was presented in February 2025, aims to accelerate commercialization through a targeted go-to-market model built around Centers of Excellence. Since the

Integrum provides operational update ahead of Q2 report

Mölndal, Sweden, October 16, 2025 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) today provides an operational update. Following the recent non-completed bid process, Integrum is taking all necessary steps to secure the company's sustainable growth. The company makes steady progress in its efforts to transform from its historical R&D focus to a more commercially oriented company. Whereas sales to date indicate that the total number of surgeries for the second quarter is likely to be in line with last year's level, the ongoing intensified marketing efforts targeting selected

Integrum provides update on OsteoCentric’s public offer and provides correction of previous announced information

Mölndal, Sweden, September 18[th], 2025  - Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B).  Reference is made to Integrum’s press release published 17 September 2025 at 00:30 CEST, in which Integrum stated it would return to the market as new information becomes available. Today, Integrum can report the following.Correction regarding acceptance forms and VP account numbers On the contrary to the press release on 17 September 2025 at 00:30 CEST, it has been established that the two acceptance forms submitted by Integrum’s founder and largest shareholder, Dr. Rickard

Integrum comments on OsteoCentric’s announcement of outcome in the public offer

Mölndal, Sweden, September 17[th], 2025  - Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) comments on OsteoCentric’s announcement of outcome in the public offer.September 16, 2025 at 07:00 CEST, OsteoCentric announced that approximately 69.4 percent of the shares in Integrum had been tendered and that the offer will not be completed as the 90 percent acceptance condition was not satisfied. Integrum disagrees with OsteoCentric's conclusion that the acceptance condition was not satisfied and wishes to further clarify its position on this matter. As previously announced in

Integrum Unveils Global Marketing Strategy at AOPA National Assembly

Mölndal, Sweden, September 4, 2025 – Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B), the provider of the OPRA™ Implant System, announced the rollout of a new global marketing strategy at the American Orthotic & Prosthetic Association’s (AOPA) National Assembly in Orlando, FL. Central to this initiative is BondedMatrix™ - a coined term designed to capture and convey the OPRA™ Implant System’s distinct ability to integrate soft tissue and bone enabling long-term outcomes to patients, clinicians, and healthcare partners worldwide.BondedMatrix™ refers to the biologically

Correction of Figures in Interim Report for the First Quarter 2025/26

When publishing the interim report for the company, it was discovered that some of the total sums in the income statement show the wrong amounts. The sum of Net Sales and Work Performed by Own Use and Activated has mistakenly included Other operating income. Moreover, Other operating expenses was summed erroneously leading to that the sum for Total Expenses showed an incorrect amount. None of the company KPI’s changes from these corrections.Therefore, the company makes the following corrections: · The total sum of income changes to 24,834 from 25,914. · Other operational income

Stronger positioning paves the way for continued growth

First quarter 2025/26 (May – July) · Net sales amounted to SEK 23.8 (18.5) million. · Operating loss totalled SEK 12.4 (12.0) million. · Profit/loss after tax amounted to SEK -10.0 (-9.4) million. · Earnings per share amounted to SEK -0.47 (-0.49) · Cash flow totalled SEK -12.4 (29.3) million. Significant events in the first quarter · In May the company appointed Martin Hillsten as the new CEO. He succeeds interim CEO Scott Flora. · Also in May, the company entered into a commercial distribution agreement with the niche company Labormed d.o.o., which distributes

Integrum AB: Invitation to the First Quarter 2025/26 Results Presentation

Mölndal, Sweden – August 28, 2025 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its first quarter 2025/26 results on September 1, 2025 at 10:00 CET.Integrum’s CEO Martin Hillsten will present the report together with CFO Jörgen Svanström in a webcast. The presentation will be held in English.   Time: Monday, September 1, 2025 at 10:00 CET. Location: Webcast (see link below). The report will be available at https://integrum.se/investor-relations/financial-reports-calendar/ The webcast and presentation material will be

Integrum secures top sponsorship title at the Global Collaborative Congress on Osseointegration exclusively for the next three years

Mölndal, Sweden, August 13, 2025 – Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B), the provider of the OPRA™ Implant System, has announced that it has secured the exclusive title of Legacy Sponsor – the highest level of sponsorship – for the Global Collaborative Congress on Osseointegration (GCCO) annual meeting, held in Charlotte, North Carolina, USA.This multi-year sponsorship grants Integrum exclusive top-tier recognition for the next three years and underscores the company’s long-standing commitment to clinical education, surgical innovation, and international

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe